The CCO role is evolving, argue John Archer and Roger Longman, as applicants must challenge entrenched views and manage a growing set of stakeholders with creativity

Leaving past limitations behind, Danish pharma widens its technology aperture to brain shuttles, AI and more  

Danish pharma eyeing growth beyond loss of exclusivity for Rexulti, aiming for broad label in rare epilepsies

AbbVie’s most recent migraine market entrant, Qulipta, showing strongest growth 

Plus: Appeals court restricts mifepristone access and updates for Lightcast, AbbVie, Regeneron, Selecta, the IRA

All seven CGRP inhibitors on the market had sales growth last quarter, with oral therapies from Pfizer and AbbVie the top performers

CHMP’s June opinions: Amylyx therapy denied, plus positive opinions for two new medicines and eight label extensions

Plus: FDA extends PDUFA for Daiichi’s quizartinib, and updates from AbbVie, Apellis and more